Faculty
Location:Home > Faculty > Faculty and Staff
 
 
Faculty and Staff
Academicians
Faculty and Staff
 
Name:
Gan Yong
Education:
Ph.D

Positions:
Professor/Ph.D candidate supervisor, Principal Investigator
Academic title:
Professor
Phone:
021-20231975
Fax:
021-20231975
E-mail:
ygan@simm.ac.cn
Personal Website:
Postal Code:
201203
Mailing Address:
501 Haike Road, Zhang Jiang Hi-Tech Park, Pudong, Shanghai, P.R.China. 201203
Resume:

Prof. Dr. Yong Gan, now serves as the principal investigator of the Centre for Drug Delivery Research in Shanghai institute of Materia Medica (SIMM), Chinese Academy of Science. He is member of the pharmaceutics committee of Chinese Pharmaceutical Association. His research interests focus on designing functional lipid drug delivery systems to overcome biological barriers for oral and intravascular drug delivery, carrying out in-depth study on drug absorption, distribution, and using this drug delivery systems to enhance biological effects of API in target tissues and to improve druggability API. He has published more than 30 peer-reviewed papers in international journals, such as Biomaterials, Drug discovery today, International Journal of Pharmaceutics. He participated in writing and editing 3 books, and holds over 40 patents (28 patents are authorized), most patents have been authorized to pharmaceutical companies and applied in industrialization.

EDUCATION
09/1997 - 06/2002 Shenyang Pharmaceutical University, School of Pharmacy, Pharmaceutics, Ph.D.
09/1993 - 06/1997 Shenyang Pharmaceutical University, School of Pharmacy, Pharmacy Analysis, B.S.

WORK EXPERIENCE
10/2008 - present Shanghai Institute of Materia Medica, Center for Drug Delivery, professor
10/2004 - 10/2008 Shanghai Institute of Materia Medica, Center for Drug Delivery, associate professor
07/2002 - 07/2004 Shanghai Institute of Materia Medica, postdoctoral fellow


Research Directions
1.Design of novel functional lipid drug delivery systems and mechanism study of overcoming biological barriers;
2.Development and industrialization of innovative drug delivery systems with time and speed controlled drug release behavior.

Social Titles
Senior member of the pharmaceutics committee of Chinese Pharmaceutical Association
Editor of the journal "China Pharmacist","Chinese Journal of Pharmaceuticals"and "Chinese Journal Pharmaceutics"

Awards & Honors
2010,Young CSPC Pharmacy Award,Chinese Pharmaceutical Association
2007,National Ministry of Education Prize for Progress in Science and Technology,China
2006,Liao Ning Province Prize for Progress in Science and Technology,China

Achievements
Based on the physiological barriers hindering efficient drug delivery, we have developed a series of functional lipid carriers for oral and intravenous drug delivery. These carriers significantly improved the biological effects of loaded drugs in the target tissues, and the mechanisms of absorption, distribution are studied in depth.
1.Oral drug delivery area Our work Focuses on the multiple biological barriers for oral delivery of poorly absorbed drug molecules including small molecules and peptide/protein macromolecules: 
   (1) Improving solubility and dissolution rate of poorly soluble drugs
   (2) Overcoming mucus barrier in GI
   (3) Overcoming the epithelial barrier in GI after drug oral delivery 
   There are more than 20 research papers of this area published in mainstream SCI journals, including Eur J Pharm Biopharm 2013, 85(3) 1325-1336; Biomaterials 2013, 34: 9678-9687; J. Pharm. Sci., 100(11), 5048-5058, 2011; Current Pharmaceutical Design, 2014,20(3):408-435; Int J Pharm. 2013,5;449(1-2):1-9; Int. J. Nanomed., 6, 3151–3162, 2011.
2.Intravascular drug delivery area A series of functional lipid carriers are designed to improve the clinical curative effect and to provide a new way for personalized medicine scheme.
   (1) Reticuloendothelial system (RES) barrier
   (2) Pathological tissue microenvironment barrier
   (3) Cell barrier
   There are 16 research papers published in mainstream SCI journals. Among them, papers published in Biomaterials. 2014, 35: 3650-3665 and Biomaterials. 2012, 33: 7103-7114 are well-reputed from international peers. This work has been cited by main pharmaceutical journals more than 100 times, and citation per paper is up to 40 times.
3.Development and industrialization of innovative pharmaceutical dosage forms In this work, we focus on design, development and industrialization of oral controlled release dosage forms including speed and time controlled release formulations. These marketed formulations have achieved excellent economic benefit. For instance, nifedipine and glipizide controlled release tablets developed by our independently developed technology have been approved by SFDA, which provided advanced controlled release dosage form with high quality and low price for patients with critical cardiovascular and cerebrovascular disease. These two products have brought huge market benefit with an annual sale of RMB 100 million and a cumulative sale of RMB 300 million. Besides, as a major research team, we also participated in the development of class A anti-cancer new drug, shimmin irinotecan hydrochloride for injection, which has been approved for clinical trials. More than 20 patents invented by our group have been granted, and 11 of them have been authorized to pharmaceutical companies. We also hold 3 PCT patents, 5 American patents, 7 clinical trial authorizations and 1 new drug certificates.

Grants & Research Projects
1.Knowledge Innovation Project in the Chinese Academy of Sciences,Development of new anti-influenza dosage forms of zanamivir,Yong Gan 2009.01-2011.01
2.CAS-NovoNordisk Research Foundation,Design of functional lipid nanoparticles for oral delivery of protein/peptide drugs and study of absorption mechanism,Project principal,2010.01-2012.12
3.National Natural Science Foundation of China,Design of novel liver targeted nano lipid carriers to inhibit efflux transporters BCRP/MRP2: reduce drug biliary excretion,Project principal,2010.01-2012.12
4.“New drug creation” National Major Science and Technology Program,Industrialization of treating schizophrenia drug paliperidone controlled release tablets,Project principal,2011.01-2013.12
5.Scientific Equipment Research and Development Project of Chinese Academy of Sciences,Design and development of high frequency ultrasonic atomizing particle preparation system with multiple point dynamic monitoring,Project principal,2012.07-2014.07
6.CAS-NovoNordisk Research Foundation,Enhancement of intestinal mucosal permeability of protein/peptide by quantum dotsamphiphilic chitosan-protein nanocomplexes loaded enteric microparticles and study of the absorption mechanism,Project principal,2013.01-2014.12
7.National Natural Science Foundation of China,Design of prodrug based on MRP3 in BL side of epithelium and the mechanism of improving oral drug absorption using smart nanocarrier,Project principal,2014.01-2017.12
8. Shanghai science and Technology Commission, Design and controllable production of drug nanocarriers with high bioavailability and the study of improving druggability of API, Project principal, 2014.01-2017.12

Pubilcations

1. Xiuying Li, Miaorong Yu, Weiwei Fn, Yong Gan*, Lars Hovgaard, Mingshi Yang. Orally active targeted drug delivery system for protiens and peptides. Expert Opin Drug Deliv, 2014, 25:1-13.

2. Xinxin Zhang, Feifei Li, Shiyan Guo, Xi Chen, Xiaoli Wang, Juan Li, Yong Gan*. Biofunctionalized polymer-lipid supported mesoporous silica nanoparticles for release of chemotherapeutics in multidrug resistant cancer cells. Biomaterials. 2014, 35(11):3650-3665.

3. Xiuying Li, Shiyan Guo, Chunliu Zhua, Quanlei Zhu, Yong Gan*, Jukka Rantanen, Ulrik Lytt Rahbek, Lars Hovgaard, Mingshi Yang. Intestinal mucosa permeability following oral insulin delivery using core shell corona nanolipoparticles. Biomaterials 2013, 34: 9678-9687.

4. Li Gan, Jing Wang, Yanan Zhao, Dan Chen, Chunliu Zhua, Jianping Liu, Yong Gan. Hyaluronan-modified core-shell liponanoparticles targeting CD44-positive retinal pigment epithelium cells via intravitreal injection. Biomaterials, 2013, 34: 5978-5987.

5. Hongzhen Yu, Dengning Xia, Quanlei Zhu, Chunliu Zhu, Dan Chen, Yong Gan. Supersaturated polymeric micelles for oral cyclosporine A delivery. Eur J Pharm Biopharm 2013, 85(3) 1325-1336.

6. Li Gan, Yi-ping Gao, Chun-liu Zhu, Xin-xin Zhang, Yong Gan*. Novel pH-sensitive lipid-polymer composite microspheres of 10-Hydroxycamptothecin exhibiting colon-specific biodistribution and reduced systemic absorption, Journal of Pharmaceutical Sciences,2013, 102(6): p. 1752-9.

7. Dan Chen; Dengning Xia; Xiuying Li; Quanlei Zhu; Hongzhen Yu; Chunliu Zhu; Yong Gan*. Comparative study of Pluronic? F127-modified liposomes and chitosan-modified liposomes for mucus penetration and oral absorption of cyclosporine A in rats. Int J Pharm. 2013,5;449(1-2):1-9.

8. Li Gan, Jing Wang, Min Jiang, Hanah Bartlett, Defang Ouyang, Frank Eperjesi, Jianping Liu, Yong Gan*, Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers, Drug Discov. Today, 18(5-6), 290-297, 2013.

9. Jiang Min, Gan Li, Zhu Chunliu, Dong Yang, Liu Jianping, Yong Gan*, Cationic core-shell liponanoparticles for ocular gene delivery, Biomaterials, 33(30), 7261-7230, 2012.

10. Zhang Xinxin, Guo Shiyan, Fan Rong, Yu Miaorong, Li Feifei, Zhu Chunliu, Yong Gan*, Dual-functional liposome for tumor targeting and overcoming multidrug resistance in hepatocellular carcinoma cells, Biomaterials, 33 (29), 7103-7114, 2012.

11. Xiuying Li, Dan Chen, Chaoyi Le, Chunliu Zhu, Yong Gan*, Lars Hovgaard, Mingshi Yang, Novel mucus-penetrating liposomes as potential oral drug delivery system: preparation, in vitro characterization, and enhanced cellular uptake, Int. J. Nanomed., 6, 3151–3162, 2011.

12. Hongzhen Yu, Sifei Han, Ping Li, Chunliu Zhu, Xinxin Zhang, Li Gan, Yong Gan*, An examination of the potential effect of lipids on the first-pass metabolism of the lipophilic drug anethol trithione, J. Pharm. Sci., 100(11), 5048-5058, 2011.

13. Jinqiu Shen, Li Gan, Chunliu Zhu, Xinxin Zhang, Yang Dong, Min Jiang, Jiabi Zhu, Yong Gan*, Novel NSAIDs ophthalmic formulation: flurbiprofen axetil emulsion with low irritancy and improved anti-inflammation effect, Int. J. Pharm., 412(1-2), 115-122, 2011.

14. Li Gan, Shun Han, Jinqiu Shen, Chunliu Zhu, Xinxin Zhang, Yong Gan*, Self-assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: improving preocular retention and ocular bioavailability, Int. J. Pharm., 396(1-2), 179-187, 2010.

15. Sifei Han, Tingting Yao, Xinxin Zhang, Li Gan, Chunliu Zhu, Hongzhen Yu, Yong Gan*, Lipid-based formulations to enhance oral bioavailability of the poorly water-soluble drug anethol trithione: effects of lipid composition and formulation, Int. J. Pharm., 379, 18-24, 2009.

16. Li Gan, Yong Gan*, Chunliu Zhu, Xinxin Zhang, Jiabi Zhu, Novel microemulsion in situ electrolyte-triggered gelling system for ophthalmic delivery of lipophilic cyclosporine A: In vitro and in vivo results, Int. J. Pharm., 365, 143-149, 2009.